key: cord-0968745-qd5ylkka
authors: Park, Joon Ho; Jiang, Yao; Zhou, Jiarong; Gong, Hua; Mohapatra, Animesh; Heo, Jiyoung; Gao, Weiwei; Fang, Ronnie H.; Zhang, Liangfang
title: Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs
date: 2021-06-16
journal: Sci Adv
DOI: 10.1126/sciadv.abf7820
sha: 915d8068beb8da2a51a10dba13a589bc54d61f7e
doc_id: 968745
cord_uid: qd5ylkka

As numerous diseases are associated with increased local inflammation, directing drugs to the inflamed sites can be a powerful therapeutic strategy. One of the common characteristics of inflamed endothelial cells is the up-regulation of vascular cell adhesion molecule–1 (VCAM-1). Here, the specific affinity between very late antigen–4 (VLA-4) and VCAM-1 is exploited to produce a biomimetic nanoparticle formulation capable of targeting inflammation. The plasma membrane from cells genetically modified to constitutively express VLA-4 is coated onto polymeric nanoparticle cores, and the resulting cell membrane–coated nanoparticles exhibit enhanced affinity to target cells that overexpress VCAM-1 in vitro. A model anti-inflammatory drug, dexamethasone, is encapsulated into the nanoformulation, enabling improved delivery of the payload to inflamed lungs and significant therapeutic efficacy in vivo. Overall, this work leverages the unique advantages of biological membrane coatings to engineer additional targeting specificities using naturally occurring target-ligand interactions.

The chemical and physiological changes associated with inflamma tion are an important part of the innate immune system (1) . Pro inflammatory processes can lead to the release of cytokines such as interleukin6 (IL6) and tumor necrosis factor, which are capable of effecting vascular changes to improve immune responses at a site of stress or injury (2) . These may include vasodilation and an increase in vascular permeability, which can promote more efficient im mune cell recruitment (3, 4) . On the cellular level, proinflammatory cytokines cause the upregulation of specific surface markers, in cluding vascular cell adhesion molecule-1 (VCAM1) or intercellu lar adhesion molecule-1 (ICAM1), which allow for immune cell adhesion at the site of inflammation (5, 6) . Although inflammation is an integral process that is required for survival, a dysregulated immune system is implicated in a wide range of disease states (7, 8) . The disease relevance of inflammation is further supported by the fact that inflammatory markers such as cellular adhesion molecules are often implicated in pathogenesis (9, 10) , and these have been explored as therapeutic and diagnostic targets.

Nanoparticlebased platforms, especially those functionalized with active targeting ligands, have the potential to serve as powerful tools for managing a wide range of diseases associated with inflamma tion (11) . Along these lines, the targeted delivery of antiinflammatory agents to the vasculature of affected sites via cell adhesion molecules represents a promising strategy (12) (13) (14) . Using inflammation as the cue, a diverse range of nanodelivery systems have been designed to target upregulated markers such as VCAM1 and ICAM1 (15) (16) (17) (18) (19) (20) , and this approach has been leveraged to treat conditions such as cancer and cardiovascular diseases (21) (22) (23) . More recently, cell membrane coating technology has garnered considerable attention in the field of nanomedicine (24, 25) . From erythrocytes to cancer cells, virtually any type of cell membrane can be coated onto the surface of nanoparticles, resulting in nanoformulations with en hanced functionality that can be customtailored to specific appli cations (26, 27) . In particular, cell membrane-coated nanoparticles have proven to be effective drug delivery systems owing to their extended circulation times and diseasehoming capabilities (26) (27) (28) . The targeting ability of these biomimetic nanoparticles is often me diated by proteins that are expressed on the source cells, and this bestows the nanoparticles with the ability to specifically interact with various disease substrates. For example, nanoparticles coated with the membrane derived from platelets were shown to specifically target bacteria as well as the exposed subendothelium in damaged vasculature (29) . A similar platform was shown to target the lungs in a murine model of cancer metastasis (30) . On top of the natural biointerfacing capabilities of cell membrane-coated nanoparticles, their traits can be further enhanced by introducing exogenous moieties onto the membrane surface. One way to achieve this is to tether targeting ligands via a lipid anchor, which can then be inserted into the cell membrane (31, 32) . Red blood cell membrane-coated nanoparticles, which exhibit prolonged blood circulation, have been functionalized in this manner to enhance their cancer target ing ability.

Instead of relying on postfabrication methods to introduce additional functionality, cell membrane-coated nanoparticles can be developed using the membrane from genetically engineered source cells (33) . A wide range of tools are available to introduce or upregulate the expression of specific surface markers (34, 35) , and this approach enables researchers to augment the functionality of cell membrane-based nanodelivery platforms based on application specific needs (36, 37) . In this study, we genetically engineered cell membrane-coated nanoparticles to specifically target sites of in flammation (Fig. 1 ). Inflamed endothelial cells are known to upregulate the expression of VCAM1 to recruit immune cells such as leuko cytes that express its cognate ligand, very late antigen-4 (VLA4) (38) . To exploit this interaction, we genetically modified a source cell line to stably express VLA4 and harvested the engineered membrane to coat polymeric nanoparticle cores. A potent antiinflammatory drug, dexamethasone (DEX), was used as a model payload to be loaded for the treatment of inflammation. The ability of the final nano formulation to target inflamed cells without compromising the ac tivity of DEX was first tested in vitro. Then, therapeutic efficacy was evaluated in vivo using a murine model of endotoxininduced lung inflammation.

VLA4 is a heterodimer that is formed by the association of integrin 4 with integrin 1 (39) . To generate a cell line constitutively dis playing the full complex, we elected to modify wildtype C1498 cells (C1498WT), which were confirmed to express high levels of integ rin 1 but lack integrin 4 ( Fig. 2A) . Following viral transduction of C1498WT to introduce the integrin 4 gene, a subpopulation of the resulting engineered cells (referred to as C1498VLA) was found to express both VLA4 components (Fig. 2B ). After success fully establishing C1498VLA, the cells were harvested and their membrane was derived by a process involving cell lysis and differ ential centrifugation. The cell membrane was then coated onto poly(lacticcoglycolic acid) (PLGA) nanoparticle cores that were prepared by a single emulsion method. Membranecoated nanoparticles prepared with the membrane from C1498WT and C1498VLA (referred to as WTNP and VLANP, respectively) both had an average diameter of approximately 175 nm, which was slightly larger than the uncoated PLGA cores (Fig. 2C ). In terms of zeta potential, the membranecoated nanoparticles exhibited a surface charge of approximately −20 mV, which was less negative than the PLGA cores (Fig. 2D ). Both the size and zeta potential data suggested proper membrane coating, which was further verified for VLANP by transmission electron microscopy, which clearly showed a mem brane layer surrounding the core (Fig. 2E ). Western blotting analy sis was used to probe for the two components of VLA4 on the nanoformulations (Fig. 2F ). As expected, both integrins 4 and 1 were found on VLANP, whereas only integrin 1 was present on WTNP. To evaluate longterm stability of the membranecoated nanoparticles, they were suspended in 10% sucrose solution at 4°C, and their size was monitored over the course of 8 weeks (Fig. 2G ). Neither nanoparticle sample exhibited a significant increase in size during this period.

The binding of VLANP was assessed in two different in vitro experiments. First, C1498WT transduced to constitutively express high amounts of VCAM1 (referred to as C1498VCAM) was used as a model target cell. The expression of VCAM1 on C1498VCAM was confirmed via flow cytometry (Fig. 3A) . Whereas the C1498WT cells did not show any expression, the C1498VCAM cells yielded a signal that was over an order of magnitude higher than the isotype control. To evaluate binding, fluorescent dye-labeled WTNP or VLANP were incubated with either C1498WT or C1498VCAM (Fig. 3 , B and C). For each pairing, the incubation was performed either with or without anti-VCAM1 to block the specific inter action between VLA4 and VCAM1. For the samples with blocking, cells were first incubated with the antibody for 30 min before nano particle treatment. After incubating with the nanoparticles for 30 min, 

the cells were washed twice and were analyzed by flow cytometry. The data revealed that there was significant nanoparticle binding only when VLANP were paired with C1498VCAM. The level of binding was reduced back to baseline levels in the presence of anti-VCAM1, thus confirming the specificity of the interaction. In con trast, there was no evidence of specific binding when VLANP were paired with C1498WT, which does not express the cognate recep tor for VLA4. The same held true for the WTNP paired with either cell type, where antibody blocking had no impact on the rel ative nanoparticle binding.

Next, we elected to study the nanoparticle binding to endothelial cells, which represent a more biologically relevant target compared to the artificially engineered C1498VCAM cells. For this purpose, we used a murine brain endothelial cell line, bEnd.3, whose VCAM1 expression can be upregulated in the presence of proinflammatory signals (40) . To induce an inflamed state, bEnd.3 cells were treated with bacterial lipopolysaccharide (LPS), and the level of VCAM1 expression was evaluated using flow cytometry (Fig. 3D ). Whereas expression of VCAM1 was near baseline levels for the untreated bEnd.3 cells, those that were treated with LPS exhibited a distinct population with elevated VCAM1. As we observed in the previous experiment with C1498VCAM cells, enhanced nanoparticle bind ing was only observed when VLANP were paired with inflamed bEnd.3 cells, and antibody blocking reduced the levels back to base line (Fig. 3 , E and F). When incubating with noninflamed bEnd.3 cells, there was no evidence of specific binding interactions, and the same held true for the control WTNP paired with bEnd.3 cells regardless of their inflammatory status. The data in these two studies confirmed the successful engineering of membranecoated nanoparticles with the ability to target inflammation based on the interaction between VLA4 and VCAM1.

As a model antiinflammatory payload, we selected DEX, which was loaded into the PLGA core by a single emulsion method before coating with either C1498WT or C1498VLA membrane to yield DEXloaded WTNP or VLANP (referred to as WTDEXNP or VLADEXNP, respectively). When the drug content was measured by highperformance liquid chromatography (HPLC), it was deter mined that the encapsulation efficiency and drug loading yield were approximately 11 and 2 weight % (wt %), respectively (Fig. 4A ). To evaluate drug release, VLADEXNP was dialyzed against a large volume of phosphatebuffered saline (PBS), and the amount of drug retained within the nanoparticles was quantified over time (Fig. 4B) . The results revealed an initial burst, where approximately 80% of the drug payload was released in the first hour, followed by a sus tained release. The release profile was in agreement with previous reports on DEXloaded PLGA formulations (41, 42) , and the data showed a good fit with the PeppasSahlin model with a regression coefficient of 0.978 (43) . To evaluate the biological activity of the DEX loaded within the nanoparticles, we used an in vitro assay based on the LPS treatment of DC2.4 dendritic cells, which causes an elevation in the levels of proinflammatory cytokines such as IL6 (Fig. 4C ). DC2.4 cells were first treated with either free DEX or VLADEXNP for 2 hours, followed by incubation with LPS over night. The supernatant was then collected to measure the concen tration of IL6 by an enzymelinked immunosorbent assay (ELISA). It was shown that both free DEX and VLADEXNP were able to attenuate IL6 secretion in a drug concentration-dependent man ner (Fig. 4D) . Although free DEX more efficiently lowered IL6 levels at drug concentrations of 0.01 and 0.1 M, the level of inflam mation was reduced to levels near baseline for both free DEX and VLADEXNP at 1 M of drug. The data indicated that the activity of the drug payload was retained after being loaded inside of VLA NP. It was confirmed that neither PLGA cores nor VLANP with out DEX loading had an impact on the level of IL6 production by the DC2.4 cells (Fig. 4E) .

After confirming the biological activity of the VLADEXNP formulation in vitro, we next sought to evaluate the formulation in vivo using a murine model of lung inflammation. The model was established by intratracheal injection of LPS directly into the lungs of BALB/c mice. To evaluate targeting ability, fluorescently labeled WTNP or VLANP were injected intravenously after the induction of lung inflammation. After 6 hours, major organs, including the heart, lungs, liver, spleen, kidneys, and blood, were collected to assess nanoparticle biodistribution (Fig. 5A) . The majority of the nanoparticles accumulated in the liver and spleen. Notably, a sig nificant increase in accumulation of VLANP was observed in the lungs compared to WTNP. This in vivo targeting result was in agreement with the in vitro findings where VLANP were able to specifically bind to inflamed cells. The safety of the formulation was assessed by monitoring the plasma levels of creatinine, a mark er of kidney toxicity that was previously studied in the context of DEX nanodelivery (44) . After 9 days of repeated daily administra tions of free DEX or VLADEXNP into healthy mice, it was shown that the creatinine concentration in mice receiving VLADEX NP remained consistent with baseline levels, whereas it was signifi cantly elevated in mice administered with free DEX (Fig. 5B) .

The therapeutic efficacy of VLADEXNP was then evaluated following the same experimental design as the targeting study. After 6 hours, the lungs were collected and homogenized, and the homo genate was then clarified by centrifugation and filtered through a 0.22m porous membrane before measuring the concentration of IL6 by ELISA. As shown in Fig. 5C , the VLADEXNP formulation was able to completely abrogate lung inflammation, while both free DEX and WTDEXNP did not have any discernable effect. The fact that WTDEXNP were not able to significantly reduce lung IL6 levels suggested that systemic exposure to DEX was not a major contributor to the efficacy observed with VLADEXNP. The efficacy of the formulation against lung inflammation was further confirmed by analyzing lung sections stained with hematoxylin and eosin (Fig. 5D) . Leukocyte recruitment and peribronchial thicken ing, which are hallmarks of lung inflammation (45, 46) , were prom inent in the lungs of mice receiving no treatment, free DEX, or WTDEXNP. In contrast, minimal leukocyte recruitment and no peribronchial thickening were observed for the group treated with VLADEXNP, and there were no other signs of toxicity present in these lung sections. Overall, the results from the in vivo studies con firmed the benefit of targeted delivery to inflamed lungs using VLANP as a drug nanocarrier.

In conclusion, we have engineered cell membrane-coated nano particles that can be used to specifically target and treat localized lung inflammation via systemic administration. A host cell positive for integrin 1 was modified to express integrin 4. Together, the two protein markers formed VLA4, which specifically interacts with VCAM1, a common marker for inflammation found on vas cular endothelia. Nanoparticles fabricated using the membrane from these genetically engineered cells were able to leverage this natural affinity to target inflamed sites, including in a murine mod el of LPSinduced lung inflammation. When the nanoparticles were loaded with DEX, an antiinflammatory drug, significant therapeu tic efficacy was achieved in vivo. Future studies will comprehen sively evaluate the safety profile of the VLADEXNP formulation, obtain additional lungspecific efficacy readouts, elucidate the optimal time window for treatment, and assess clinical relevance using additional animal models of severe inflammatory disease. As pathological inflammation is heavily implicated in a number of important disease conditions (7, 47) , the reported biomimetic plat form could be leveraged to improve the in vivo activity of various therapeutic payloads through enhanced targeting. Notably, VCAM 1 upregulation has been observed in renal pathologies as well as in inflamed cerebral vasculature (48, 49) . In addition, DEX has been shown to be effective at managing the inflammation associated with COVID19 (50), and a targeted formulation capable of localizing the drug to the lungs may help to further boost its therapeutic profile. In this work, we specifically engineered the nano particles to display VLA4, which is a complex, multicomponent membranebound ligand that would otherwise be infeasible to incorporate us ing traditional synthetic strategies. This highlights the advantages of using genetic engineering techniques to expand the wideranging utility of cell membrane coating technology. In particular, the generalized application of this approach would enable researchers to streamline the development of new targeted nanoformulations by using targetligand interactions that occur in nature. Combined with the biocompatibility and biointerfacing characteristics that are in herent to cell membrane coatings, the work presented here could initiate a new wave of biomimetic nanomedicine with finely crafted functionalities. 

Engineered C1498VLA and C1498VCAM cells were created by transducing C1498WT. Briefly, the genes for integrin 4 (MG50049M, Sino Biological) and VCAM1 (MG50163UT, Sino Biological) gene were cloned into pQCXIP and pQCXIH plasmids (Clontech), respectively, using an InFusion HD cloning kit (Clontech) following the manufacturer's protocol, yielding pQCXIP4 and pQCXIHVCAM1. AmphoPhoenix cells were plated onto 100mm tissue culture dishes containing 10 ml of medium at 3 × 10 5 cells/ml and cultured overnight. The cells were transfected with pQCXIP4 or pQCXIHVCAM1 using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. The supernatant of the transfected AmphoPhoenix was collected and used to resuspend C1498WT cells, which were then centrifuged at 800g for 90 min. After the spin, the transduced cells were incubated for 4 hours before the media were changed with fresh media. Fluorescently labeled antibodies, including FITC (fluorescein isothiocyanate) antimouse CD49d (R12, BioLegend), Alexa647 antimouse/rat CD29 (HM11, BioLegend), or PE (phycoerythrin) antimouse CD106 (STA, BioLegend), were used to assess the expression levels of VLA4 or VCAM1. Data were collected using a Becton Dickinson FACSCantoII flow cytometer and analyzed using FlowJo software. All of the engineered cells were sorted using a Becton Dickinson FACSAriaII flow cytometer to select for cells expressing high levels of VLA4 or VCAM1.

The membranes from C1498WT and engineered C1498VLA cells were derived using a previously described method with some modifi cations (51) . First, the cells were harvested and washed in a starting buffer containing 30 mM trisHCl (pH 7.0) (Quality Biological) with 0.0759 M sucrose (SigmaAldrich) and 0.225 M dmannitol (SigmaAldrich). The washed cells were resuspended in an isolation buffer containing 0.5 mM ethylene glycolbis(aminoethyl ether) N,N,N′,N′tetraacetic acid (SigmaAldrich), a phosphatase inhibitor cocktail (SigmaAldrich), and a protease inhibitor cocktail (Sigma Aldrich). Then, the cells were homogenized using a Kinematica Polytron PT 10/35 probe homogenizer at 70% power for 15 passes. The homogenate was first centrifuged at 10,000g in a Beckman Coulter Optima XPN80 ultracentrifuge for 25 min. The superna tant was then collected and centrifuged at 150,000g for 35 min. The resulting pellet of cell membrane was washed and stored in a solution containing 0.2 mM ethylenediaminetetraacetic acid (USB Corpora tion) in UltraPure DNasefree/RNasefree distilled water (Invitrogen). Total membrane protein content was quantified by a BCA protein assay kit (Pierce).

Polymeric cores were prepared by a single emulsion process using carboxylterminated 50:50 PLGA (0.66 dl/g; LACTEL absorbable polymers). For DEXloaded PLGA cores, 500 l of PLGA (50 mg/ml) in dichloromethane (DCM; SigmaAldrich) was mixed with 500 l of DEX (10 mg/ml) in acetone. This mixture was added to 5 ml of 10 mM trisHCl (pH 8) and sonicated using a Thermo Fisher Scientific 150E Sonic Dismembrator at 70% power for 2 min. The sonicated mixture was added to 10 ml of 10 mM trisHCl (pH 8) and was magneti cally stirred at 700 rpm overnight. For 1,1′dioctadecyl3,3,3′,3′ tetramethylindodicarbocyanine (DiD, ex/em = 644/663 nm; Biotium) labeling, 500 l of PLGA (50 mg/ml) in DCM was mixed with 500 l of DiD (20 g/ml) in DCM. This mixture was added to 5 ml of 10 mM trisHCl (pH 8) and sonicated using a Thermo Fisher Scientific 150E Sonic Dismembrator at 70% power for 2 min. The sonicated mixture was added to 10 ml of 10 mM trisHCl (pH 8) and was magnetically stirred at 700g for 3 hours. Empty PLGA core preparation followed the same procedure, except substituting the DiD solution for 500 l of neat DCM. To coat the polymeric cores with cell membranes, the nanoparticle cores were first centrifuged at 21,100g for 8 min. The pellets were resuspended in solution con taining membranes derived from C1498WT or C1498VLA. The mixture was sonicated in a 1.5ml disposable sizing cuvette (BrandTech Scientific Inc.) using a Thermo Fisher Scientific FS30D bath sonica tor at a frequency of 42 kHz and a power of 100 W for 3 min. For the in vitro studies, UltraPure water and sucrose were added to adjust the polymer concentration to 1 mg/ml and the sucrose concentra tion to 10%. For the in vivo studies, UltraPure water and sucrose were added to adjust the polymer concentration to 10 mg/ml and the su crose concentration to 10%.

The size and surface zeta potential of WTNP and VLANP were measured by dynamic light scattering using a Malvern ZEN 3600 Zetasizer. For electron microscopy visualization, a VLANP sample was negatively stained with 1 wt % uranyl acetate (Electron Micros copy Sciences) on a carboncoated 400mesh copper grid (Electron Microscopy Sciences) and visualized using a JEOL 1200 EX II trans mission electron microscope. The presence of VLA4 on WTNP and VLANP was determined using western blotting. First, the samples were adjusted to 1 mg/ml protein content, followed by the addition of NuPAGE 4× lithium dodecyl sulfate sample loading buffer (Novex) and heating at 70°C for 10 min. Then, 25 l was loaded into the wells of 12well Bolt 4 to 12% BisTris gels (Invitrogen) and ran at 165 V for 45 min in MOPS running buffer (Novex). The proteins were transferred for 60 min at a voltage of 10 V onto 0.45m nitrocellulose membranes (Pierce) in Bolt transfer buffer (Novex). Nonspecific interactions were blocked using 5% milk (Genesee Scientific) in PBS (Thermo Fisher Scientific) with 0.05% Tween 20 (National Scientific). The blots were probed using antiintegrin 4 antibody (B2, Santa Cruz Biotechnology) or antiintegrin 1 anti body (E11, Santa Cruz Biotechnology). The secondary staining was done using the corresponding horseradish peroxidase-conjugated antibodies (BioLegend). Membranes with stained samples were devel oped in a dark room using ECL western blotting substrate (Pierce) and an ImageWorks MiniMedical/90 Developer. Longterm stability of WTNP and VLANP in 10% sucrose solution was tested by storing the particles at 4°C for 2 months with weekly size measurements.

The expression level of VCAM1 on C1498WT, C1498VCAM, untreated bEnd.3 cells, and bEnd.3 cells treated overnight with LPS (1 g/ml) from Escherichia coli K12 (LPS; InvivoGen) was evaluated as described above. For the first binding study, 5 × 10 4 cells, either C1498WT or C1498VCAM, were collected and resuspended in 160 l of DMEM containing 0.5% USDA FBS, 1% bovine serum albumin (BSA; SigmaAldrich), and 1 mM MnCl 2 (SigmaAldrich). For blocking, antimouse CD106 antibody was added to the cells, followed by incubation at 4°C for 30 min. Then, 40 l of DiD (1 mg/ml)labeled WTNP or VLANP was added, and the mixture was incu bated at 4°C for another 30 min. After washing the cells twice with PBS, the fluorescent signals from the cells were detected using flow cytometry. For the second study, 5 × 10 4 bEnd.3 cells were plated and then either left untreated or pretreated with LPS overnight. The media were then removed and replaced with 160 l of DMEM con taining 0.5% USDA FBS, 0.8% BSA, and 1 mM MnCl 2 . For block ing, antimouse CD106 antibody was added to the cells, followed by incubation at 4°C for 30 min. Then, 40 l of DiD (1 mg/ml)-labeled WTNP or VLANP was added, and the mixture was incubated at 4°C for another 30 min. After washing the cells twice with PBS, the cells were detached by scraping, and the fluorescent signals from the cells were detected using flow cytometry. All data were collected using a Becton Dickinson FACSCantoII flow cytometer and ana lyzed using FlowJo software.

Drug loading and encapsulation efficiency were measured using HPLC on an Agilent 1220 Infinity II gradient liquid chromatogra phy system equipped with a C18 analytical column (Brownlee). VLADEXNP samples were dissolved overnight in 80% acetonitrile (ACN; EMD Millipore) and then centrifuged at 21,100g for 8 min to collect the supernatant for analysis. The solutions were run through the column at a flow rate of 0.3 ml/min and DEX was detected at a wavelength of 242 nm. The DEX release profile was obtained by loading 200 l of VLADEXNP (1 mg/ml) into SlideALyzer MINI dialysis devices (10K molecular weight cutoff; Thermo Fisher Scien tific) and floating them on 1 liter of PBS stirred at 150 rpm. At each time point, dialysis cups were retrieved, and their contents were centrifuged at 21,100g for 8 min. The pellets were dissolved in 80% ACN overnight and processed as described above for HPLC analysis.

The biological activity of DEX was evaluated in vitro using a test system involving the LPS treatment of DC2.4 dendritic cells. To val idate the system, DC2.4 cells were first plated onto a 24well tissue culture plate at 5 × 10 4 cells per well and cultured overnight with or without LPS at a concentration of 1 g/ml. Then, supernatant was collected, and the concentration of IL6 was measured using a mouse IL6 ELISA kit (BioLegend) according to the manufacturer's protocol. To compare free DEX and VLADEXNP, the two formu lations were first added to the culture medium at final drug concen trations of 0.01, 0.1, and 1 M, followed by 2 hours of incubation. For free DEX, 1000× stock solutions were prepared at 0.01, 0.1, and 1 mM in dimethyl sulfoxide. Then, the cells were treated with LPS overnight before measuring the concentration of IL6 in the super natant. To test the effect of empty nanoparticles, either PLGA cores or VLANP at a final concentration of 1 g/ml were first incubated with the cells for 2 hours, followed by an overnight incubation either with or without LPS before measuring IL6 levels.

All animal experiments were performed in accordance with the National Institutes of Health (NIH) guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California San Diego. To induce lung inflammation in mice, 30 l of LPS (400 g/ml) in PBS was injected intratracheally into male BALB/c mice (Charles River Laboratories). At 1 hour after LPS injection, 100 l of DiD (10 mg/ml)-labeled WTNP or VLANP was administered intravenously. After 6 hours, the heart, lungs, liver, spleen, kidneys, and blood were collected. All solid tissues were washed with PBS and suspended in 1 ml of PBS before being homogenized with a Biospec MiniBeadbeater16. The homoge nates and blood were then diluted 4× with PBS and added to a 96 well plate, and fluorescence was measured using a BioTek Synergy Mx microplate reader. For each sample, the background signal measured from the corresponding organ or blood of control mice that did not receive any treatment was subtracted.

Male BALB/c mice were intravenously injected with 100 l of free DEX or VLADEXNP, each at a drug concentration of 200 g/ml, daily for the first 7 days. Then, for the next 2 days, the dosage was doubled by injecting 200 l of each formulation at the same drug concentration. At 24 hours after the last injection, blood was col lected by submandibular puncture and collected into tubes contain ing sodium heparin (SigmaAldrich). Plasma samples were obtained by taking the supernatant of the blood after centrifuging at 800g for 10 min. Creatinine levels were measured using a creatinine colori metric assay kit (Cayman Chemical Company) according to the manufacturer's protocol.

To treat lung inflammation, male BALB/c mice were first intratra cheally challenged with 30 l of LPS (400 g/ml) in PBS. At 1 hour after the challenge, 100 l of free DEX, WTDEXNP, and VLA DEXNP, each at a drug concentration of 200 g/ml, was injected intravenously. After 6 hours, the lungs were collected and homoge nized as described above. The homogenates were centrifuged at 10,000g, and the supernatants were filtered through 0.22m poly vinylidene difluoride syringe filters (CELLTREAT). The concentra tion of IL6 was measured using a mouse IL6 ELISA kit according to the manufacturer's protocol. For histology analysis, the lungs were collected after 6 hours and fixed in 10% phosphatebuffered formalin (Fisher Chemical) for 24 hours. The fixed lungs were sec tioned, followed by hematoxylin and eosin (Sakura Finetek) stain ing. Histology slides were prepared by the Moores Cancer Center Tissue Technology Shared Resource (Cancer Center Support Grant P30CA23100). Images were obtained using a Hamamatsu NanoZoomer 2.0HT slide scanner and analyzed using the NanoZoomer Digital Pathology software.

A guiding map for inflammation

Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo

Role of inflammatory mediators in angiogenesis

Effects of systemic inflammation on endothelium-dependent vasodilation

Cytokine regulation of cellular adhesion molecule expression in inflammation

Modulating leukocyte recruitment in inflammation

Homeostasis, inflammation, and disease susceptibility

Inflammation, ageing and chronic disease

A major role for VCAM-1, but not ICAM-1, in early atherosclerosis

Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis

Biomimetic nanoparticles for inflammation targeting

Nanocarriers for vascular delivery of anti-inflammatory agents

Endothelial targeting of antibody-decorated polymeric filomicelles

Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes

Targeting rapamycin to podocytes using a vascular cell adhesion molecule-1 (VCAM-1)-harnessed SAINT-based lipid carrier system

Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia

VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression

Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers

ICAM-1 recycling in endothelial cells: A novel pathway for sustained intracellular delivery and prolonged effects of drugs

Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress

Active targeting of early and mid-stage atherosclerotic plaques using self-assembled peptide amphiphile micelles

VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice

Programmable nanoparticle functionalization for in vivo targeting

Cell membrane-derived nanomaterials for biomedical applications

Cell membrane coating nanotechnology

Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery

Erythrocyte membranecamouflaged polymeric nanoparticles as a biomimetic delivery platform

Biomimetic strategies for targeted nanoparticle delivery

Nanoparticle biointerfacing by platelet membrane cloaking

Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles

Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles

A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery

Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity

Genetic transformation

CRISPR-Cas guides the future of genetic engineering

Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: A versatile platform for cancer virotherapy

Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy

Leukocyte migration into inflamed tissues

Characterization of the cell surface heterodimer VLA-4 and related peptides

Borrelia burgdorferi upregulates the adhesion molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on mouse endothelioma cells in vitro

Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery

Encapsulation of dexamethasone into biodegradable polymeric nanoparticles

A simple equation for the description of solute release. III. Coupling of diffusion and relaxation

Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis

B lymphocytes regulate airway granulocytic inflammation and cytokine production in a murine model of fungal allergic asthma

Therapeutic effects of histone deacetylase inhibitors in a murine asthma model

Inflammation and cancer

Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier

Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo

Dexamethasone in hospitalized patients with Covid-19

Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity